Literature DB >> 29194722

The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response.

Wenshi Wang1, Yijin Wang2, Changbo Qu1, Shan Wang2, Jianhua Zhou1,3, Wanlu Cao1, Lei Xu1, Buyun Ma1, Mohamad S Hakim1,4, Yuebang Yin1, Tiancheng Li5, Maikel P Peppelenbosch1, Jingmin Zhao2, Qiuwei Pan1.   

Abstract

The outcomes of hepatitis E virus (HEV) infection are diverse, ranging from asymptomatic carrier, self-limiting acute infection, and fulminant hepatitis to persistent infection. This is closely associated with the immunological status of the host. This study aimed to understand the innate cellular immunity as the first-line defense mechanism in response to HEV infection. Phosphorylation of signal transducer and activator of transcription 1, a hallmark of the activation of antiviral interferon (IFN) response, was observed in the liver tissues of the majority of HEV-infected patients but not in the liver of uninfected individuals. In cultured cell lines and primary liver organoids, we found that HEV RNA genome potently induced IFN production and antiviral response. This mechanism is conserved among different HEV strains, including genotypes 1, 3, and 7 as tested. Interestingly, single-stranded HEV RNA is sufficient to trigger the antiviral response, without the requirement of viral RNA synthesis and the generation of an RNA replicative form or replicative intermediate. Surprisingly, the m7 G cap and poly A tail are not required, although both are key features of the HEV genome. Mechanistically, this antiviral response occurs in a retinoic acid-inducible gene-I-independent, melanoma differentiation-associated protein 5-independent, mitochondrial antiviral signaling protein-independent, and β-catenin-independent but IRF3-dependent and IRF7-dependent manner. Furthermore, the integrity of the Janus kinase-signal transducer and activator of transcription pathway is essentially required.
CONCLUSION: HEV infection elicits an active IFN-related antiviral response in vitro and in patients, triggered by the viral RNA and mediated by IFN regulatory factors 3 and 7 and the Janus kinase-signal transducer and activator of transcription cascade; these findings have revealed new insights into HEV-host interactions and provided the basis for understanding the pathogenesis and outcome of HEV infection. (Hepatology 2018;67:2096-2112).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29194722     DOI: 10.1002/hep.29702

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Modulation of SOCS3 Levels via STAT3 and Estrogen-ERαp66 Signaling during Hepatitis E Virus Replication in Hepatocellular Carcinoma Cells.

Authors:  Harini Sooryanarain; C Lynn Heffron; Hassan M Mahsoub; Anna M Hassebroek; Bo Wang; Debin Tian; S Ansar Ahmed; Xiang-Jin Meng
Journal:  J Virol       Date:  2022-09-14       Impact factor: 6.549

2.  Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable.

Authors:  Yang Li; Peifa Yu; Amy L Kessler; Jingyi Shu; Xiaoyan Liu; Zhaochao Liang; Jiaye Liu; Yunlong Li; Pengfei Li; Ling Wang; Yining Wang; Zhongren Ma; Aixia Liu; Ling Wang; Marco J Bruno; Robert A de Man; Maikel P Peppelenbosch; Sonja I Buschow; Lin Wang; Yijin Wang; Qiuwei Pan
Journal:  Hepatology       Date:  2021-12-05       Impact factor: 17.298

3.  Th1/Th2 Cells and Associated Cytokines in Acute Hepatitis E and Related Acute Liver Failure.

Authors:  Jian Wu; Yurong Guo; Xuan Lu; Fen Huang; Feifei Lv; Daqiao Wei; Anquan Shang; Jinfeng Yang; Qiaoling Pan; Bin Jiang; Jiong Yu; Hongcui Cao; Lanjuan Li
Journal:  J Immunol Res       Date:  2020-11-17       Impact factor: 4.818

4.  Chronic Hepatitis E is associated with cholangitis.

Authors:  Andrea Beer; Heidemarie Holzmann; Sven Pischke; Patrick Behrendt; Fritz Wrba; Jerome Schlue; Uta Drebber; Barbara Neudert; Emina Halilbasic; Hans Kreipe; Ansgar Lohse; Martina Sterneck; Heiner Wedemeyer; Michael Manns; Hans P Dienes
Journal:  Liver Int       Date:  2019-06-17       Impact factor: 5.828

Review 5.  The Interplay between Host Innate Immunity and Hepatitis E Virus.

Authors:  Yang Li; Changbo Qu; Peifa Yu; Xumin Ou; Qiuwei Pan; Wenshi Wang
Journal:  Viruses       Date:  2019-06-11       Impact factor: 5.048

Review 6.  Cell Culture Models for Hepatitis E Virus.

Authors:  Rebecca Menhua Fu; Charlotte Caroline Decker; Viet Loan Dao Thi
Journal:  Viruses       Date:  2019-07-03       Impact factor: 5.048

7.  The U-Rich Untranslated Region of the Hepatitis E Virus Induces Differential Type I and Type III Interferon Responses in a Host Cell-Dependent Manner.

Authors:  Harini Sooryanarain; Connie L Heffron; Xiang-Jin Meng
Journal:  mBio       Date:  2020-01-14       Impact factor: 7.867

8.  Evaluation of the neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and red cell distribution width for the prediction of prognosis of patients with hepatitis B virus-related decompensated cirrhosis.

Authors:  XinKe Li; JianPing Wu; WeiLin Mao
Journal:  J Clin Lab Anal       Date:  2020-07-14       Impact factor: 2.352

Review 9.  Hepatitis E Virus: How It Escapes Host Innate Immunity.

Authors:  Sébastien Lhomme; Marion Migueres; Florence Abravanel; Olivier Marion; Nassim Kamar; Jacques Izopet
Journal:  Vaccines (Basel)       Date:  2020-07-28

10.  Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids.

Authors:  Pengfei Li; Yunlong Li; Yijin Wang; Jiaye Liu; Marla Lavrijsen; Yang Li; Ruyi Zhang; Monique M A Verstegen; Yining Wang; Tian-Cheng Li; Zhongren Ma; Denis E Kainov; Marco J Bruno; Robert A de Man; Luc J W van der Laan; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Sci Adv       Date:  2022-01-19       Impact factor: 14.136

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.